A Phase II Clinical Study on Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2019
Price : $35 *
At a glance
- Drugs Palbociclib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 08 Jun 2019 Status changed from not yet recruiting to active no longer recruiting.
- 04 Jun 2019 Primary endpoint (Overall response rate) has been met as per results presented at 55th Annual Meeting of the American Society of Clinical Oncology.
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology